Literature DB >> 18490764

Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation.

Wei Xu1, Stefan P Berger, Leendert A Trouw, Hetty C de Boer, Nicole Schlagwein, Chantal Mutsaers, Mohamed R Daha, Cees van Kooten.   

Abstract

Cells that undergo apoptosis or necrosis are promptly removed by phagocytes. Soluble opsonins such as complement can opsonize dying cells, thereby promoting their removal by phagocytes and modulating the immune response. The pivotal role of the complement system in the handling of dying cells has been demonstrated for the classical pathway (via C1q) and lectin pathway (via mannose-binding lectin and ficolin). Herein we report that the only known naturally occurring positive regulator of complement, properdin, binds predominantly to late apoptotic and necrotic cells, but not to early apoptotic cells. This binding occurs independently of C3b, which is additional to the standard model wherein properdin binds to preexisting clusters of C3b on targets and stabilizes the convertase C3bBb. By binding to late apoptotic or necrotic cells, properdin serves as a focal point for local amplification of alternative pathway complement activation. Furthermore, properdin exhibits a strong interaction with DNA that is exposed on the late stage of dying cells. Our data indicate that direct recognition of dying cells by properdin is essential to drive alternative pathway complement activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490764     DOI: 10.4049/jimmunol.180.11.7613

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  66 in total

1.  Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement.

Authors:  Viviana P Ferreira; Claudio Cortes; Michael K Pangburn
Journal:  Immunobiology       Date:  2010-02-12       Impact factor: 3.144

Review 2.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

3.  Native properdin binds to Chlamydia pneumoniae and promotes complement activation.

Authors:  Claudio Cortes; V P Ferreira; Michael K Pangburn
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

4.  Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury.

Authors:  Yuko Kimura; Lin Zhou; Takashi Miwa; Wen-Chao Song
Journal:  J Clin Invest       Date:  2010-10       Impact factor: 14.808

5.  Molecular MRI of acute necrosis with a novel DNA-binding gadolinium chelate: kinetics of cell death and clearance in infarcted myocardium.

Authors:  Shuning Huang; Howard H Chen; Hushan Yuan; Guangping Dai; Daniel T Schuhle; Choukri Mekkaoui; Soeun Ngoy; Ronglih Liao; Peter Caravan; Lee Josephson; David E Sosnovik
Journal:  Circ Cardiovasc Imaging       Date:  2011-08-11       Impact factor: 7.792

6.  Properdin homeostasis requires turnover of the alternative complement pathway.

Authors:  Xiaobo Wu; Thomas Q Xu; John P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

7.  Alternative complement pathway induction by ANCA.

Authors:  Hans U Lutz
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

8.  Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo.

Authors:  Jie Tian; Zhili Xu; Jeffrey S Smith; Sean E Hofherr; Michael A Barry; Andrew P Byrnes
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

Review 9.  Age-related macular degeneration: activation of innate immunity system via pattern recognition receptors.

Authors:  K Kaarniranta; A Salminen
Journal:  J Mol Med (Berl)       Date:  2008-11-14       Impact factor: 4.599

10.  Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes.

Authors:  Azusa Hashimoto; Yusuke Suzuki; Hitoshi Suzuki; Isao Ohsawa; Rhubell Brown; Stacy Hall; Yuichi Tanaka; Jan Novak; Hiroyuki Ohi; Yasuhiko Tomino
Journal:  Am J Pathol       Date:  2012-08-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.